SB 202190

SB 202190 is a selective and cell-permeable inhibitor of p38 MAPK (IC50s: 50/100 nM for p38α/p38β).

There are many small molecules used in reprogramming, which can be categorized into four types: metabolic regulators, epigenetic modifiers, signaling modulators, and aging inhibitors. In this issue, we introduce three commonly used small molecule signaling modulators in reprogramming: 1) A 83-01 and SB-431542 inhibit the activity of TGF-β type I receptors ALK5/4/7 kinases. TGF-β plays a crucial role in stem cell culture. Stem cells possess active paracrine functions and can secrete a large amount of transforming growth factors through exosomes. TGF-β promotes stem cell proliferation, aiding in the maintenance of their numbers. A 83-01 and SB-431542, as TGF-β inhibitors, are commonly used to inhibit the differentiation of iPSCs and maintain the self-renewal of cells in vitro. A 83-01 is generally used for the culture of gastrointestinal, hepatic, prostatic, and mammary organoids, while SB-431542 is typically used for the culture of lung and inner ear organoids. 2) SB 202190 is a potent p38 MAPK kinase inhibitor that can induce human embryonic stem cells to differentiate into cardiac muscle cells and promote the self-renewal of neural stem cells. It can be used for the culture of gastrointestinal, mammary, and prostatic organoids.

152121-30-7

C20H14FN3O

SB 202190, also known as FHPI, is a selective inhibitor of p38 MAPK. It inhibits p38α and p38β2 with IC50 values of 50 nM and 100 nM, respectively. Additionally, it has demonstrated efficacy in rescuing memory impairments and exhibits anticancer activity. SB 202190 can also be used in organoid culture.

331.35

Autophagy; MAPK; Apoptosis

0.9984

Organoid

Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1

Apoptosis; p38 MAPK; Autophagy